ReseaRch aRticle
Pharmacogenomics (2012) 13(10), [1119] [1120] [1121] [1122] [1123] [1124] [1125] [1126] [1127] Antipsychotic drug dosage and therapeutic response in schizophrenia is influenced by ABCB1 genotypes: a study from a south Indian perspective Schizophrenia is a burden for the affected, their families and health systems all over the world and a large portion of this economic burden is attributed to the therapeutic aspects of the disease. Approximately 70% of patients fail to experience at least minimal response early on in treatment [1, 2] . The trial and error mode of antipsychotic treatment result in symptom exacerbations, relapse, loss of employment, social dysfunction, medical morbidity, suicide and increased risk of hospitalization with resultant higher costs of treatment [3, 4] . These factors strongly reinforce the need for pharmacogenetic research to venture into parameters affecting antipsychotic response and thereby to predict favorable clinical outcomes. To better understand the characteristics of the group of patients who are nonresponsive to treatment and finetune the treatment options, pharmacogenetic data may provide meaningful insights into predicting the drug response in p sychiatric disorders [5, 6] .
Pharmacogenetics has received a great deal of interest in schizophrenia as pharmacotherapy is the first line of treatment for the psychotic symptoms experienced by patients. Most of the published articles on pharmacoresistant schizophrenia has focused on polymorphisms in drug targets (neurotransmitter receptors) and drug-metabolizing enzymes, mainly CYP2D6 [7] . These studies, although informative, were not consistent in predicting response to anti psychotics. An array of drug transporters are now being considered for pharmacoresistance, amongst them, P-glycoprotein (P-gp) coded for by ATP-binding cassette, subfamily B (MDR/TAP), member 1 (ABCB1) holds a significant importance. Recent reports demonstrated that drugs such as risperidone, olan zapine, clozapine, haloperidol and quetiapine have varying degrees of affinity for P-gp [8] [9] [10] . In a conventional clinical setting with 1-year follow-up, polypharmacy has been the routine practice worldwide [11] . There are hardly any clinical trial data or other sources of evidence to support the rational of poly pharmacy usage and its dosage prescriptions. Unlike epilepsy, refractoriness in schizophrenia has no surgical option. Therefore, identifying risk genotypes and dosage monitoring based on risk genotype is an ideal scenario. Very few studies have been conducted to investigate the influence of ABCB1 polymorphisms as a cause of pharmacoresistance in schizophrenia.
P-gp, a member of the highly conserved superfamily of ATP-binding cassette (ABC) Aim: The conventional practice of using trial and error mode to select antipsychotic drugs in treatment of schizophrenia can result in symptom exacerbations, relapse and severe side effects, resulting in higher costs of treatment. P-glycoprotein (ABCB1) is known to regulate the concentration of antipsychotic drugs in the brain. Variable expressivity based on polymorphism in the gene ABCB1 may reflect on the drug response and its relationship to dosage. Materials & methods: All antipsychotic dosages administered to patients were converted to common chlorpromazine equivalents. Response to antipsychotics was based on 50% cutoff in Brief Psychiatric Rating Scale ratings after 1-year of follow-up. Using a case-control study design, ABCB1 polymorphisms were screened in 192 individuals grouped into responders and nonresponders. Results: A strong allelic, genotypic and haplotypic association, was observed, which was predictive of good response to antipsychotics. Individuals carrying the favorable homozygous genotypes of rs1045642 and rs2032582 displayed better response with increased dosage while those carrying risk genotype manifested refractoriness on increased dosage. Conclusion: The study suggests that a priori knowledge of ABCB1 genotypes can provide a significant input into evaluating the patient's response to medication, and minimizing redundant dosing and refractoriness.
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transporter proteins is encoded by the ABCB1 gene on chromosome 7. It is a plasma membrane protein with 1280 amino acids that weighs around 170 kDa, has two transmembrane domains each containing six membrane-spanning helices and an ATP-binding site that can actively transport its substrates against a concentration gradient [12] . P-gp is expressed in the blood-brain barrier and therefore can have a profound effect in regulating the concen tration of psychotropic drugs in the brain, and this may limit the bioavailability and therapeutic window of many drugs [13, 14] . Genetic variants in ABCB1 have been associated with altered expression [15, 16] . Hence, it could be interpreted that polymorphisms in this gene may influence intracerebral antipsychotic concentration in a dose-dependent manner and combination of drugs in polypharmacy might also influence the therapeutic response. Therefore, a priori know ledge of relevant ABCB1 genotypes of patients might prevent the trial and error mode of drug administration and could minimize the drug-related side effects resulting in reduced economic burden of medication.
The objective of the current study was to investigate the role of three important polymorphisms C1236T (rs1128503), G2677T/A (rs2032582) and C3435T (rs1045642) in ABCB1 in influencing antipsychotic response and dosing strategies in schizophrenic patients in a south Indian population. ABCB1 C3435T, a synonymous SNP in exon 27 and G2677T and G2677A polymorphisms that results in Ala893Ser and Ala893Thr amino acid changes, respectively, can alter expression and activity of P-gp [15, 16] . These SNPs are reported to be in linkage disequilibrium with a synonymous SNP in exon 13 (1236C>T), therefore these SNPs were chosen to identify their role in association with altered antipsychotic response in schizophrenic patients from south India.
Materials & methods
n Patient selection Patients for pharmacogenomic assessment were selected from two hospitals in south India. Patients were selected based on their ethnic, geographical and social considerations. This was duly taken care of by selecting our patient population from the Malayalam-speaking genetically homo genous Dravidian populations, particularly from the state of Kerala. Genetic distance-based relationship of Malayalam-speaking Dravidian communities with reference to north Indian and other global population is reviewed extensively in the authors' earlier publication [17] . Assessment of response to antipsychotics was based on information from the hospitals' mental healthcare records and personal interview with each patient. Two independent psychiatrists assessed the patient history, diagnosis and medication of these patients. All the patients were diagnosed clinically as per the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for mental disorders as described earlier [18] . Baseline rating of these drug naive patients based on the Extended Brief Psychiatric Rating Scale (BPRS-E; 24 item, score 1-7) [19] was noted at the time of first consultation. Medication profile was monitored for all the follow-up periods. The psychiatrists were completely blinded regarding the patient's genotype during the treatment and assessment. The study was undertaken in its natural setting; therefore the medication or dosages were administered by the psychia trists as per the patient's feedback. Feedback on the patients discomforts were recorded by the psychiatrist. Patients' discomfort such as sedation and dizziness were recorded as side effects but were not rated during the followup periods. Details of the patient characteristics in the study are given in Table 1 . During the 1-year follow-up the majority of the patients were prescribed with both typical and atypical antipsychotics as per their medical requirements. The most frequently administered antipsychotic drugs were clozapine, haloperidol and risperidone. Drug dosage of all antipsychotics was converted to common chlorpromazine equivalents (CPZeq) [20] . One-year follow-up was considered for evaluating the treatment response. Clinical improvement was assessed by percent change scores between initial baseline Brief Psychiatric Rating Scale (BPRS) score and BPRS score after 1-year follow-up [21] . Out of 243 patients initially recruited for the study, 192 completed the 1-year follow-up assessment and selection criteria. Patients with drug or alcohol abuse and with a history of neuro logical or somatic disease that are likely to precipitate psychotic symptoms such as hypo thyroidism were excluded from the study. Patients with improvement of 50% or more in their BPRS ratings after 1-year follow-up were classified as 'responders' and others as 'nonresponders' to antipsychotics.
n Sample collection & genotyping Peripheral blood was collected from all the indivi duals in ethylenediaminetetraacetic acid-coated vials. The study was approved by the institutional ethics committee for biomedical subjects that met the Indian Council for Medical Research guidelines. Genomic DNA was isolated from lymphocytes using future science group Antipsychotic drugs & therapeutic response in schizophrenia & ABCB1 genotypes ReseaRch aRticle the conventional phenol-chloroform method. Three polymorphisms in ABCB1: C1236T (rs1128503); G2677T/A (rs2032582); and C3435T (rs1045642) were analyzed. Selected polymorphisms in ABCB1 were genotyped using the primer sets and PCR conditions as described earlier [22] .
n Statistical analysis The percentage BPRS change from baseline to study end point (B%) for each participant was calculated using the formula: where B 0 = BPRS at baseline, B 1 = BPRS after 1-year follow-up, and with 24 being the minimum score of the BPRS in the 1-7 rating system [23] . Allele, genotype and haplotype frequency was calculated with the software COCAPHASE program of the UNPHASED software version 3.1, using the expectation-maximization to estimate frequencies with 1000 permutations [24, 101] . Statistical comparison of clinical variables and categorical data between the responsive and nonresponsive patient groups were analyzed using c 2 test [102] . Fisher's exact test was used wherever necessary. Odds ratios (OR) and their 95% CIs were estimated for the effects of specified alleles. To construct haplotype block, pairwise linkage disequilibrium statistics, measured by standardized D´, were estimated using Haploview 4.1 [25, 103] . The power of the genotype association was tested using the software Power for Association With Error version 1.2 [26, 104] . We used a model-free approach for calculations of power for a fixed sample size, where the allele and genotype frequencies of SNP markers were known in both the responder and nonresponder groups. The power calculations were carried out assuming the Douglas Skol Boehnke error model with parameter settings of g (0.01) and h (0.01) at 5% level of significance [27] . Paired t-test was used to identify the variation in dosing regimen among responders and nonresponders with reference to their genotypes. The criterion for s ignificance was set at p < 0.05.
Results
n Phenotype response to therapy Out of 243 patients initially selected, 51 were excluded due to regional differences in ethnic profile, irregular follow-up, drug abuse (substance abuse) or alchohol abuse. Concomitant use of other therapeutic drugs was not prohibited. Patients who fulfilled the criterion for selection were classified as responders and nonresponders based on 50% improvement in BPRS rating after 1 year of antipsychotic treatment. According to this criterion, 130 (68%) patients with 1-year follow-up could be classified as responders to medication and 62 (32%) fell into the category of nonresponders to antipsychotic medication. The patient character istics were analyzed separately in responders and nonresponders (Table 1) . Mean change in the BPRS ratings scores after 1 year of antipsychotic medication was 27.95 in the responder group and 11 in the nonresponder group. This corres ponded in mean percentage change in BPRS scores in responder and nonresponder groups to be to 76.02 and 29.02%, respectively. The mean age of onset was also found to be margin ally lower in the non responder group when compared with the responder group. While comparing the average antipsychotic dose converted to its CPZeq (given as mean ± standard Figure 1) . While evaluating the patients' records we observed that side effects such as sedation and dizziness were more frequently reported in patients with 1236TT, 2677TT and 3435TT genotypes.
Discussion
The practice of antipsychotic prescriptions had always been based on a feedback mechanism. The present study is unique in its design since the objective was to understand the practice of antipsychotic prescription and evaluate its response based on the pharmacogenetic background. The practice of prescription in the present study was based on restoring normalcy at whatever cost and therefore not controlling for any specific medicine, unlike many other studies that were based on a single drug [28] [29] [30] . Most of the earlier studies based on response rating and monitoring were studied from a few weeks to several months [31] , while the present study is based on a 1-year follow-up. The response rating was carried out using most commonly used the BPRS rating scale. From a clinical perspective, 50% cutoff on the BPRS rating score has been considered ideal, as it is believed that even in acutely ill, well-responding participants a cutoff reflecting much improvement (50% BPRS reduction) would be more meaningful than a higher or a minimal threshold for response [23] . While dissecting the patient group into responder and nonresponder groups, based on the BPRS rating score, after a 1-year followup period, it was observed that the nonresponder group was given a comparatively higher dosage of CPZeq of antipsychotic drugs. This dosing requirement was further investigated in relation to ABCB1 polymorphism, unlike in most of the earlier studies that restricted their therapeutic response to monotherapy in different populations. These studies provide conflicting insights into population-specific differences. While evaluating the genotype patterns to therapeutic response, it was observed that the 1236C and 3435C alleles and their homozygous genotypes were strongly associated with better response. This observation is in sharp contrast with earlier reports on the role of 2677TT and 3435TT genotypes on olanzapine [28] and 1236TT on risperidone [30] , as associated with better response. Interestingly, both these studies were based on monotherapy, while the present study is based on combination therapy, and it was observed that the TT genotype is associated with refractoriness to anti psychotic drugs. These observations are interesting, since it is known that both typical and atypical antipsychotics can act, differentially, as a substrate, inhibitor and inducer of P-gp activity in a dose-dependent manner [7] . Therefore, observations from monotherapy and polytherapy could be tangentially different. In a recent review on different individual antipsycotics the allelic response of C3435T has been reported to vary significantly [10] . This is reflected in recent monotherapy studies with respect to clozapine and olanzapine where different C3435T genotypic variants have been implicated with good response [32, 33] . However, this further implies that genotype response to combination therapy and monotherapy could be mutually exclusive. This needs further investigation. The majority of the studies to date suggest that the variant 3435C allele is associated with increased P-gp activity, resulting in higher plasma concentrations of its substrates [34] . This clarifies the observation of this study on use of higher dosage of CPZeq of antipsychotics in C allele and CC genotype individuals having better response in contrast with its alternate allele and its homozygous genotype individuals. While comparing the genotypes and dosing patterns in the responders it can be suggested that the genotypes, which were associated with good response, were able to tolerate higher dosage of CPZeq in comparison with its alternate genotype. Polypharmacy and higher dosing patterns had been a common practice among psychiatrists to attain maximum response to medication. The observation of this study regarding higher dosage of CPZeq in individuals with 1236TT, 2677TT and 3435TT genotypes in non responders suggests that possibly in these individuals the [35, 36] . A recent study also reported that ABCB1 3435 T allele and ABCB1 2667 T-3435 T haplotype carriers were frequent among subjects with extrapyramidal syndromes [37] . In a similar study on short-term risperidone therapy, akathisia and dystonia were observed to be associated with G2677T/A and C3435T genotypes; however, this was not found to be associated with gene-dose effect [38] . Thus in a combination therapy, although higher dosing was associated with response, this dosing was distinctly dependent on genotype of an individual. This study suggests that ABCB1 genotyping prior to medication can provide significant input in the understanding of patients' response. In addition, if the dosing requirement is based on genotypes, side effects of medication can possibly be further minimized to a great extent. In conventional practice the objective is to control the symptoms of schizophrenia by altering the drug or increasing the dosage. Use of highdose antipsychotic regimens in the management of patients with schizophrenia is a common practice among psychiatrists throughout the world. Ethnic disparities in dosage prescription patterns of antipsychotic medications among black Africans, African-Americans, Orientals and Caucasians have been reported. The subSaharan African countries distinctly differ in standard prescription guidelines published for use in western parts of the world [39, 40] . The ethnic differences in their genetic make up may also influence the pharmaco dynamic and pharmacokinetic parameters of psychotropic medications [10, 41] . This is further justified by considering the ethnic variation in ABCB1 genotypes in the global population. The 3435C allele frequency for C3435T poly morphism varies from 34 to 90% [105] . Close to 80% of the Ghanaian, Kenyan, African-American and Sudanese populations are homozygous for the C allele (3435CC), whereas T-allele frequencies are almost 50% for Caucasians and Asians. Allele frequencies in the studied population were comparable with Chinese and Japanese data for ABCB1. However, homozygous 3435CC genotypes were not common in south Asian populations. Very few studies have been carried out pertaining to bioavailability of antipsychotics in relation to ethnic variability or genetic variability. Asian-Americans reportedly have significantly higher serum levels of haloperidol [42] . Higher serum haloperidol levels were observed in healthy Americans of far-eastern ancestry when compared with white volunteers. In a later study it was further demonstrated that Asian-Americans with schizophrenia responded optimally to signi ficantly lower [42] . In a similar study reduced haloperidol plasma levels and steady state halo peridol ratios were reported to be lower in Chinese patients when compared with non-Chinese patients [43] . Not many studies exist with reference to ethnicity and plasma concentration of second-generation antipsychotics. In a recent study C3435T TT homozygotes have been reported to have higher plasma concentrations of clozapine compared with CC homozygotes in Caucasian population [32] . With respect to plasma levels of risperidone and ABCB1 genotypes no such correlation could be established, but with respect to treatment response different genotypes of C3435T were observed to be associated with Caucasians, Chinese, Japanese and healthy Koreans [30, 37, 38, 44] . Thus, interethnic differences in allelic distribution are proposed to be an underlying factor for observed interethnic variability in bioavailability and response to different drugs. This also possibly suggests that geno-ethnicity-specific dosing regimens would be highly appropriate for the global management of s chizophrenia instead of a un iversal dosing regimen.
The present study is an exploratory study in a subset of an Indian population, but needs to be validated further in a larger sample size. Although there appears to be a significant association of ABCB1 polymorphisms and antipsychotic response, this needs to be confirmed further with other pharmacogenetic variants and their plasma concentration of the drugs administered. Plasma concentrations of drugs are influenced by various metabolic factors and comedication, therefore interpretation of plasma levels should be integrated with other pharmacogenetic and metabolic variants, comedications, pathology of disease, food and age. Extrapolating this work further to other populations would need to establish a consensus approach for defining pharmaco resistance in schizophrenia at least in
Executive summary

Present practice of medication & role of drug transporter in therapeutic response
Polytherapy and high-dose antipsychotic regimens is a common practice among psychiatrists in the management of schizophrenia throughout the world. P-glycoprotein functions as an efflux transporter in a wide variety of cells that include the cells of the GI tract, blood cells, biliary tract, kidney and brain. This may alternatively reflect its role in absorption, distribution and elimination of various xenobiotics.
Understanding the medication practice based on ABCB1
Polymorphisms in the ABCB1 gene may influence intracerebral antipsychotic concentration in a dose-dependent manner and combination of drugs in polypharmacy might also influence the therapeutic response and resultant refractoriness. The study was set in its conventional therapeutic background with an objective to attain maximal response. The most frequently administered antipsychotic drugs were clozapine, haloperidol and risperidone. Drug dosages of all antipsychotics were converted to a common chlorpromazine equivalent (CPZeq). Patients with improvement of 50% or more in their Brief Psychiatric Rating Scale ratings after 1-year follow-up were classified as 'responders' and others as 'nonresponders' to antipsychotics. Mean change in the Brief Psychiatric Rating Scale ratings scores after 1 year of antipsychotic medication was 27.95 in the responder group and 11 in the nonresponder group. This corresponded in mean percentage change in brief psychiatric rating scale scores in responder and nonresponder groups to be 76.02 and 29.02%, respectively. Responders were given an average CPZeq of 537.21 ± 48.37 mg per day while nonresponders were given 622.22 ± 109.8 mg per day. A strong allelic (1236C; p = 0.02, 3435C; p = 0.03), genotypic (3435CC; p = 0.01) and haplotypic (1236C-2677G-3435C; p = 0.03) association, that was predictive of good response to antipsychotics was observed. The favorable homozygous genotypes of C3435T (CC vs TT; p = 0.0053) and G2677T (GG vs TT; p = 0.0093), individuals were able to tolerate higher CPZeq of antipsychotics resulting in better response while risk genotype individuals at higher CPZeq resulted in refractoriness.
Conclusion
In a combination therapy the response to higher dosing was distinctly dependent on genotype of an individual. ABCB1 genotyping also supports the idea that geno-ethnicity-specific dosing regimens would be highly appropriate for the management of schizophrenia, globally instead of a universal dosing regimen.
Future perspective
A priori knowledge of ABCB1 genotypes can provide significant input in patient response, minimize redundant dosing and prevent refractoriness. Ethnic disparities in dosage prescription pattern of antipsychotic medications among black Africans, African-Americans, Orientals and Caucasian have been reported that could be attributed to genotype response. Extrapolating this work further to other populations would need to establish a consensus approach for defining pharmacoresistance in schizophrenia at least in terms of evaluation period, cutoff for response and a common equivalence.
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terms of evaluation period, cutoff for response and a c ommon equivalence.
Conclusion
The present study attempts to understand the practice of antipsychotic dosing patterns in a conventional clinical set up and its implications on therapeutic response based on individual genotype. Our study suggests that a priori knowledge of ABCB1 genotypes can provide significant input in patient response, minimize redundant dosing and prevent refractoriness. ABCB1 genotyping also justifies that geno-ethnicity-specific dosing regimen would be highly appropriate for the management of schizophrenia, globally and not as a universal dosing regimen. Pharmacogenetic testing is likely to be the golden standard for all therapeutic dosing strategies in future and therefore for anti psychotics treatment it should be extended to ABCB1 genotyping too. Any observation on conventional dosing strategies based on ethnicity, environment and genotypes would be a step forward towards rational use of anti psychotics. This strategy would help in minimizing randomized dosing, the side effects and resultant cost factor for medication. nn Importance of drug-drug interaction in combination therapy and its influence on P-glycoprotein expression is discussed. Typical and atypical antipsychotics can act, differentially, as a substrate, inhibitor and inducer of P-glycoprotein activity.
